Uncategorized

Second rejection for tumor destroyer puts Replimune on a ‘challenging path’

Second rejection for tumor destroyer puts Replimune on a ‘challenging path’

Published

on

Replimune’s CEO Sushil Patel has already warned that the biotech will need to cut staff and substantially scale back its U.S. manufacturing operations.​ ​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version